LHCG Produces Solid 3Q Results

Oppenheimer has published a research report on LHC Group, Inc. LHCG following 3Q results that were above expectations and came as a result of strong top-line growth. In the report, Oppenheimer writes "LHCG produced solid results, reporting Q3:10 EPS of $0.73, compared to our estimate of $0.71 and the Street consensus of $0.70. The beat was driven by strong top-line growth, which exceeded our estimate handily ($166.6M vs. $159.1M estimate). Following the quarter, LHC Group increased its revenue expectations to a range of $625M-635M (up from $615M-625M), but maintained '10 EPS guidance of $2.75-$2.85. Furthermore, the company announced a $50M share repurchase authorization. Overall, this was a strong quarter and although the regulatory environment remains challenging, we believe this is a good time to establish a long-term position in LHC Group." Oppenheimer maintains its Outperform rating and $36 price target. LHC Group closed yesterday at $26.79.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsHealth CareHealth Care ServicesLHC GroupOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!